Hao Zhou

Hao Zhou has extensive work experience in the field of business development and investment. Hao is currently serving as the Vice President of Global Business Development at Legend Biotech, a position they have held since February 2023. Prior to that, they were the Global Head of Business Development at PTC Therapeutics, Inc. from March 2022 to October 2022. Hao also worked as the Vice President of Business Development at Ultragenyx Pharmaceutical Inc. from September 2020 to March 2022 and as the Executive Director of Business Development from April 2018 to August 2020. Before that, they held the role of Senior Director of Business Development at BioMarin Pharmaceutical Inc. from November 2011 to March 2018. Hao also has experience as a Vice President of Business Development at NovaMed Pharmaceutical Inc. from October 2007 to March 2010 and as a Director of Business Development at SciClone Pharmaceuticals from October 2006 to October 2007. Prior to their roles in the pharmaceutical industry, Hao worked as a Vice President of Healthcare Venture Capital Investment at New Leaf Venture Partners/Sprout Group, a Credit Suisse affiliate, from March 2002 to October 2006 and as an Associate in Global Healthcare Investment Banking at Merrill Lynch from September 2001 to December 2001. Hao began their career as a Scientist in Drug Discovery at Regeneron Pharmaceuticals, Inc. from January 1997 to August 1999.

Hao Zhou holds a Master of Business Administration (MBA) degree in Finance from The Wharton School. Additionally, they have a Doctor of Philosophy (PhD) degree in Molecular Biology & Genetics from The Johns Hopkins University School of Medicine. Hao earned their Bachelor of Science (BS) degree in Genetics from Fudan University.